Mucormycosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Aditya Ganti (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Posaconazole has been found to be an effective agent for secondary prevention of mucormycosis. | [[Posaconazole]] has been found to be an effective agent for secondary prevention of mucormycosis. | ||
== Secondary Prevention in Mucormycosis<ref name="pmid21622653">{{cite journal |vauthors=Kontoyiannis DP, Lewis RE |title=How I treat mucormycosis |journal=Blood |volume=118 |issue=5 |pages=1216–24 |year=2011 |pmid=21622653 |pmc=3292433 |doi=10.1182/blood-2011-03-316430 |url=}}</ref> == | == Secondary Prevention in Mucormycosis<ref name="pmid21622653">{{cite journal |vauthors=Kontoyiannis DP, Lewis RE |title=How I treat mucormycosis |journal=Blood |volume=118 |issue=5 |pages=1216–24 |year=2011 |pmid=21622653 |pmc=3292433 |doi=10.1182/blood-2011-03-316430 |url=}}</ref> == | ||
*Patients who respond to a parenteral lipid amphotericin B-based treatment, given for at least 3 weeks, are transitioned to oral posaconazole as maintenance/secondary prophylaxis with serial monitoring of posaconazole serum drug concentrations to ensure compliance and absorption of the antifungal. | *Patients who respond to a parenteral lipid amphotericin B-based treatment, given for at least 3 weeks, are transitioned to oral posaconazole as maintenance/secondary prophylaxis with serial monitoring of posaconazole serum drug concentrations to ensure compliance and absorption of the antifungal. | ||
Revision as of 19:51, 14 June 2017
|
Mucormycosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]
Overview
Posaconazole has been found to be an effective agent for secondary prevention of mucormycosis.
Secondary Prevention in Mucormycosis[1]
- Patients who respond to a parenteral lipid amphotericin B-based treatment, given for at least 3 weeks, are transitioned to oral posaconazole as maintenance/secondary prophylaxis with serial monitoring of posaconazole serum drug concentrations to ensure compliance and absorption of the antifungal.
- Lipid amphotericin B may achieve high levels in the human tissues, thus, intermittent doses of lipid amphotericin B (ie, 5 mg/kg 3 times per week or possibly even 2 times per week) after at least 3 to 4 weeks of initial therapy as an alternative to posaconazole therapy may also be used.
References
- ↑ Kontoyiannis DP, Lewis RE (2011). "How I treat mucormycosis". Blood. 118 (5): 1216–24. doi:10.1182/blood-2011-03-316430. PMC 3292433. PMID 21622653.